- Home
- UPXI vs ATXI Comparison
UPXI vs ATXI Comparison
Compare UPXI & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- ATXI
- Stock Information
- Founded
- UPXI 2018
- ATXI 2015
- Country
- UPXI United States
- ATXI United States
- Employees
- UPXI N/A
- ATXI N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- ATXI Health Care
- Exchange
- UPXI Nasdaq
- ATXI Nasdaq
- Market Cap
- UPXI 4.6M
- ATXI 3.7M
- IPO Year
- UPXI 2021
- ATXI 2017
- Fundamental
- Price
- UPXI $2.92
- ATXI $1.36
- Analyst Decision
- UPXI Hold
- ATXI
- Analyst Count
- UPXI 1
- ATXI 0
- Target Price
- UPXI $25.00
- ATXI N/A
- AVG Volume (30 Days)
- UPXI 71.1K
- ATXI 1.1M
- Earning Date
- UPXI 02-14-2025
- ATXI 03-17-2025
- Dividend Yield
- UPXI N/A
- ATXI N/A
- EPS Growth
- UPXI N/A
- ATXI N/A
- EPS
- UPXI N/A
- ATXI N/A
- Revenue
- UPXI $18,625,089.00
- ATXI N/A
- Revenue This Year
- UPXI $299.03
- ATXI N/A
- Revenue Next Year
- UPXI N/A
- ATXI N/A
- P/E Ratio
- UPXI N/A
- ATXI N/A
- Revenue Growth
- UPXI 4.75
- ATXI N/A
- 52 Week Low
- UPXI $2.17
- ATXI $1.22
- 52 Week High
- UPXI $15.91
- ATXI $15.00
- Technical
- Relative Strength Index (RSI)
- UPXI 34.56
- ATXI 41.78
- Support Level
- UPXI $3.35
- ATXI $1.33
- Resistance Level
- UPXI $4.50
- ATXI $1.44
- Average True Range (ATR)
- UPXI 0.36
- ATXI 0.09
- MACD
- UPXI -0.06
- ATXI 0.02
- Stochastic Oscillator
- UPXI 5.39
- ATXI 63.64
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.